Management Of Heart Failure Patients Research Articles

Could internal jugular vein ultrasound be useful in the assessment of patients with heart failure? A systematic review

Many recent studies have validated the internal jugular vein ultrasound (IJV-US) ultrasound for estimating volemic status in critical patients. If research confirms its accuracy in detecting intravascular volume, congestion, and prognosis, this method could help manage heart failure (HF) because it is simple, fast, and applicable in several settings. This review examines the IJV-US’s reliability, diagnostic accuracy, and ability to predict poor outcomes for HF, as well as its correlation with surrogate congestion tests like natriuretic peptides and elevated central venous pressure (CVP). Our systematic review followed the PRISMA statement for systematic reviews and meta-analyses. Eleven studies examined the reliability and validity of IJV-US measures in predicting congestion, volume status, and prognosis in adult spontaneously breathing HF patients. We searched PubMed, Cochrane Library, and EMBASE. IJV-US measurements using Valsalva and sniffing seem more accurate for predicting congestion, volume status, high CVP, and poor prognosis. The IJV ratio in chronic HF and out-hospital patients and the absence of IJV area [cross-sectional area (CSA)] changes in acute HF (AHF) and in-hospital patients are the most validated measurements. No evidence suggests the method is reliable between and within raters. AHF patients’ IJV ratio and CSA absence appear to correlate with CVP and atrial natriuretic peptides. In conclusion, the IJV-US may be useful for managing HF patients, but more research is needed to confirm its reliability and prognostic accuracy. Develop a standard US protocol lastly.

The management of heart failure patients in a value-based healthcare system: The role of cardiac biomarkers

The management of heart failure patients in a value-based healthcare system: The role of cardiac biomarkers

Clinical impact of remote heart failure management using the multiparameter ICD HeartLogic alert

Introduction and objectivesThe multiparametric implantable cardioverter-defibrillator HeartLogic index has proven to be a sensitive and timely predictor of impending heart failure (HF) decompensation. We evaluated the impact of a standardized follow-up protocol implemented by nursing staff and based on remote management of alerts. MethodsThe algorithm was activated in HF patients at 19 Spanish centers. Transmitted data were analyzed remotely, and patients were contacted by telephone if alerts were issued. Clinical actions were implemented remotely or through outpatient visits. The primary endpoint consisted of HF hospitalizations or death. Secondary endpoints were HF outpatient visits. We compared the 12-month periods before and after the adoption of the protocol. ResultsWe analyzed 392 patients (aged 69±10 years, 76% male, 50% ischemic cardiomyopathy) with implantable cardioverter-defibrillators (20%) or cardiac resynchronization therapy defibrillators (80%). The primary endpoint occurred 151 times in 86 (22%) patients during the 12 months before the adoption of the protocol, and 69 times in 45 (11%) patients (P<.001) during the 12 months after its adoption. The mean number of hospitalizations per patient was 0.39±0.89 pre- and 0.18±0.57 postadoption (P<.001). There were 185 outpatient visits for HF in 96 (24%) patients before adoption and 64 in 48 (12%) patients after adoption (P<.001). The mean number of visits per patient was 0.47±1.11 pre- and 0.16±0.51 postadoption (P<.001). ConclusionsA standardized follow-up protocol based on remote management of HeartLogic alerts enabled effective remote management of HF patients. After its adoption, we observed a significant reduction in HF hospitalizations and outpatient visits.

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review.

Background: Heart failure (HF) affects around 60 million individuals worldwide. The primary aim of this study was to evaluate the efficacy of lung ultrasound (LUS) in managing HF with the goal of reducing hospital readmission rates. Methods: A systematic search was conducted on PubMed, Embase, Google Scholar, Web of Science, and Scopus, covering clinical trials, meta-analyses, systematic reviews, and original articles published between 1 January 2019 and 31 December 2023, focusing on LUS for HF assessment in out-patient settings. There is a potential for bias as the effectiveness of interventions may vary depending on the individuals administering them. Results: The PRISMA method synthesized the findings. Out of 873 articles identified, 33 were selected: 19 articles focused on prognostic assessment of HF, 11 centred on multimodal diagnostic assessments, and two addressed therapeutic guidance for HF diagnosis. LUS demonstrates advantages in detecting subclinical congestion, which holds prognostic significance for readmission and mortality during out-patient follow-up post-hospital-discharge, especially in complex scenarios, but there is a lack of standardization. Conclusions: there are considerable uncertainties in their interpretation and monitoring changes. The need for an updated international consensus on the use of LUS seems obvious.

Point of Care Ultrasound for Diagnosis and Management in Heart Failure: A Targeted Literature Review.

Cardiac point of care ultrasound (POCUS) has shown increasing utility as a tool for diagnosing and managing heart failure (HF). Within cardiology, intravascular volume assessment leveraging visualization of the inferior vena cava (IVC) is a central aspect of care, as IVC size correlates with central venous pressure. This targeted literature review aimed to examine the existing literature assessing the use of POCUS in diagnosis and management of HF patients utilizing POCUS-based IVC measurement either alone or in combination with secondary methods. A targeted PubMed and Ovid database search up until August 28, 2023 using a keyword search was completed. Studies that did not include IVC assessment with POCUS in HF were excluded. The initial search using both PubMed and Ovid resulted in 370 journal publications. After exclusion criteria were used 15 studies were included in the review.Studies were grouped into three categories: 1) how well POCUS was able to identify HF, 2) whether POCUS-based findings correlated with other measures evaluating HF and was able to predict the effect of diuretic administration, and 3) whether POCUS-based findings served as a good prognostic indicator. The 5 studies that evaluated HF identification with POCUS found that both diagnostic sensitivity and specificity may reach 90%-100% when IVC measurement was coupled with a lung ultrasound assessing the presence of B-lines or pleural effusion. Five studies assessing POCUS findings correlating with other HF measures and diuretic effect found that IVC diameter changed significantly with diuretic administration (p<0.05). All 6 studies assessing POCUS as a predictor of long-term mortality or hospital readmission found measures that achieved statistical significance with p<0.05. Including POCUS as standard-of-care - both as a diagnostic tool in the emergency department and a management tool in in-patient and out-patient facilities - may improve the treatment of HF.

Optimizing the management of heart failure: structuring the care pathway

The incidence of chronic heart failure continues to rise in Western countries, justifying the implementation of an optimized multidisciplinary organization based on medical and nursing convergence. Around the main heart failure, assistance and transplantation unit at Toulouse University Hospital, several structures have been put in place to better manage heart failure patients and improve their care pathway.

Efficacy of Native T1 Mapping for Patients With Non-Ischemic Cardiomyopathy and Ventricular Functional Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.

We investigated the efficacy of left ventricular (LV) myocardial damage by native T1mapping obtained with cardiac magnetic resonance (CMR) for patients undergoing transcatheter edge-to-edge repair (TEER).Methods and Results: We studied 40 symptomatic non-ischemic heart failure (HF) patients and ventricular functional mitral regurgitation (VFMR) undergoing TEER. LV myocardial damage was defined as the native T1Z-score, which was converted from native T1values obtained with CMR. The primary endpoint was defined as HF rehospitalization or cardiovascular death over 12 months after TEER. Multivariable Cox proportional hazards analysis showed that the native T1Z-score was the only independent parameter associated with cardiovascular events (hazard ratio 3.40; 95% confidential interval 1.51-7.67), and that patients with native T1Z-scores <2.41 experienced significantly fewer cardiovascular events than those with native T1Z-scores ≥2.41 (P=0.001). Moreover, the combination of a native T1Z-score <2.41 and more severe VFMR (effective regurgitant orifice area [EROA] ≥0.30 cm2) was associated with fewer cardiovascular events than a native T1Z-score ≥2.41 and less severe VFMR (EROA <0.30 cm2; P=0.002). Assessment of baseline LV myocardial damage based on native T1Z-scores obtained with CMR without gadolinium-based contrast media is a valuable additional parameter for better management of HF patients and VFMR following TEER.

Obesity: the perfect storm for heart failure.

Obesity condition causes morphological and functional alterations involving the cardiovascular system. These can represent the substrates for different cardiovascular diseases, such as atrial fibrillation, coronary artery disease, sudden cardiac death, and heart failure (HF) with both preserved ejection fraction (EF) and reduced EF. Different pathogenetic mechanisms may help to explain the association between obesity and HF including left ventricular remodelling and epicardial fat accumulation, endothelial dysfunction, and coronary microvascular dysfunction. Multi-imaging modalities are required for appropriate recognition of subclinical systolic dysfunction typically associated with obesity, with echocardiography being the most cost-effective technique. Therapeutic approach in patients with obesity and HF is challenging, particularly regarding patients with preserved EF in which few strategies with high level of evidence are available. Weight loss is of extreme importance in patients with obesity and HF, being a primary therapeutic intervention. Sodium-glucose co-transporter-2 inhibitors have been recently introduced as a novel tool in the management of HF patients. The present review aims at analysing the most recent studies supporting pathogenesis, diagnosis, and management in patients with obesity and HF.

Development and validation of algorithms to predict left ventricular ejection fraction class from healthcare claims data.

The use of large medical or healthcare claims databases is very useful for population-based studies on the burden of heart failure (HF). Clinical characteristics and management of HF patients differ according to categories of left ventricular ejection fraction (LVEF), but this information is often missing in such databases. We aimed to develop and validate algorithms to identify LVEF in healthcare databases where the information is lacking. Algorithms were built by machine learning with a random forest approach. Algorithms were trained and reinforced using the French national claims database [Système National des Données de Santé (SNDS)] and a French HF registry. Variables were age, gender, and comorbidities, which could be identified by medico-administrative code-based proxies, Anatomical Therapeutic Chemical codes for drug delivery, International Classification of Diseases (Tenth Revision) coding for hospitalizations, and administrative codes for any other type of reimbursed care. The algorithms were validated by cross-validation and against a subset of the SNDS that includes LVEF information. The areas under the receiver operating characteristic curve were 0.84 for the algorithm identifying LVEF≤40% and 0.79 for the algorithms identifying LVEF<50% and ≥50%. For LVEF≤40%, the reinforced algorithm identified 50% of patients in the validation dataset with a positive predictive value of 0.88 and a specificity of 0.96. The most important predictive variables were delivery of HF medication, sex, age, hospitalization, and testing for natriuretic peptides with different orders of positive or negative importance according to the LVEF category. The algorithms identify reduced or preserved LVEF in HF patients within a nationwide healthcare claims database with high positive predictive value and low rates of false positives.

Low Mean Perfusion Pressure Indexed to Body Surface Area is a Powerful Predictor of Poor Outcomes After Heart Transplantation in Patients With High Pre-Transplant Venous Pressure: A Clinical Study With Physiological Insights From Mathematical Modelling of Biventricular Heart Failure

The deleterious consequences of chronically elevated venous pressure in patients with profound right ventricular or biventricular dysfunction are well known, including renal and hepatic dysfunction, and volume overload. The only option for these patients, if they fail optimal medical treatment, is a heart transplant, as they are not candidates for left ventricular assist device therapy. Mean perfusion pressure (MPP) is important in the outcomes of critically ill patients with high venous pressure. The question arises whether MPP is important for the outcomes of heart transplants in patients with elevated pre-transplant venous pressure. Medical management of heart failure patients with reduced ejection fraction involves lowering the systemic afterload with vasodilators while awaiting a transplant. We hypothesised that when venous pressure is elevated prior to transplant, a substantial reduction in systemic arterial elastance (Ea) through vasodilation may significantly decrease MPP, resulting in compromised end-organ function and consequent unfavourable outcomes after heart transplantation. This study aims to investigate whether a low MPP serves as a risk factor for adverse outcomes in heart transplant recipients with high venous pressure. A retrospective analysis was conducted on 250 heart transplant recipients undergoing isolated heart transplantation at a single institution from October 2012 to March 2020. Right atrial pressure (RAP) of more than 15 mmHg was considered high. Additionally, Ea calculated as the ratio of end-systolic pressure to stroke volume, and MPP calculated as the difference between mean arterial pressure and RAP were considered in our analysis. The outcomes of transplantation were measured in terms of 90-day mortality and survival up to 7 years. High RAP was a significant risk factor for short-term and medium-term survival if Ea was low (<2.7 mmHg/mL, the median value). This group had 39.39% in-hospital mortality compared to 14.49% for RAP<15 mmHg (p∼0.005). When Ea was high, this difference in survival was not evident: 8% for RAP<15 mmHg vs 4.8% for RAP>15 mmHg (p∼0.550). This effect was mediated through a lower MPP, and the mortality due to lower MPP increased strikingly with higher body surface area (BSA). A negative correlation was observed between MPP indexed to BSA (MPPI) and the Model for End-Stage Liver Disease score (r∼-0.3580, p<0.0001) as well as creatinine (r∼-0.3551, p<0.0001). MPPI less than 40 mmHg/m2 was associated with poorer short-term (23.2% for MPPI<40 mmHg/m2 vs 7.1% for MPPI>40 mmHg/m2, p∼0.001) and medium-term survival. The impact of high RAP and low Ea on survival was evident even on medium-term follow-up; only 30% survival at 7 years follow-up for high RAP and low Ea vs 75% for RAP<15 mmHg (p∼0.0033). The acceptable blood pressure during vasodilator therapy in patients with high RAP needs to be higher, especially in those with higher BSA. MPPI less than 40 mmHg/m2 is a risk factor for survival, in the short and medium-term, after heart transplantation.

Unmet needs in end-of-life care for heart failure patients

ObjectiveTo investigate end-of-life (EoL) care for heart failure (HF) in Tuscany (Italy) from healthcare professionals' perspective and identify areas for intervention. MethodsAll the directors of Cardiology units (n = 29) and palliative care (PC) units (n = 14) in Tuscany were surveyed on the practices of EoL care. ResultsForty-five percent of cardiologists reported that their hospital had some EoL care services for HF patients. However, 75% did not have a multidisciplinary team providing EoL care for HF patients. Sixty-four percent stated that <25% of patients who might benefit from PC did receive it, and 18% stated that no patient received PC. For most of PC specialists, HF patients accounted for <25% of their patients. PC specialists believed that patients with cancer diseases were much more likely to receive PC than HF patients at EoL, and 36% judged that almost no HF patients were timely referred to hospice care. The majority of PC specialists reported that almost no HF patient prepared advance healthcare directives, as opposite to 57% for cancer patients, suggesting poor understanding or acceptance of their terminal condition. ConclusionsThe management of HF patients in the EoL stage in Tuscany is often suboptimal. EoL care should be implemented to ensure an adequate quality of life to these patients.

The Six-Minute Walk as A Safety Exercise in Improving the Health-Related Quality of Life Among Heart Failure Patients: A Preliminary Research

The prevalence of heart failure patients is steadily increasing worldwide. The quality of life among them was also shown to be decreasing day by day. Inadequate health-related quality of life in heart failure patients leads to an increase in mortality rate. Thus, effective management of heart failure patients is essential. The present study was to examine the intervention based on the six-minute walk test to improve health-related quality of life for patients with heart failure. A quasi-experimental study was conducted in the cardiovascular center of the acute care setting. The Six-minute Walk Test (6MWT), in accordance with the American Thoracic Society guideline, was implemented as the intervention procedure. The Minnesota Living with Heart Failure (MLWHF) was used to measure the health-related quality of life of patients. Fifteen heart failure patients enrolled in the study for a month; 73.3% were male with a mean age of 57.47 (SD 14.32). Overall, the health-related quality of life in heart failure patients was poor at the baseline of the study, then their quality of life significantly increased to good quality after implementing the 6MWT. An improvement in the functional performance was also found among them. This study indicates that the 6MWT was suitable, safe, and simply performed in heart failure patients, which can effectively improve the health-related quality of life of patients with heart failure.

Retracted: Effect of Mobile Internet Technology in Health Management of Heart Failure Patients Guiding Cardiac Rehabilitation

Retracted: Effect of Mobile Internet Technology in Health Management of Heart Failure Patients Guiding Cardiac Rehabilitation

Treatment characteristics and factors associated with heart failure with improved ejection fraction in the heart failure patient management program at Hanoi Heart Hospital

Background: Many patients with heart failure (HF) with reduced ejection fraction (HFrEF) have improved or restored left ventricular ejection fraction (LVEF). Within context heart failure with recovered or improved ejection fraction (HFiEF) has been proposed as a new category of HF. Data on clinical characteristics, outcomes, and medical, interventional, surgical, or related factors in patients with heart failure with improved ejection fraction (HFiEF) are scarce. Methods: Descriptive analysis study, the period from May 2021 to November 2022 satisfies the criteria for heart failure with reduced or slightly reduced ejection fraction and is hospitalized for inpatient treatment, discharged from the hospital to participate in the patient management program heart failure for at least 3 months. Results: 488 patients were included in the study, the average age of the improved group and the remaining group were 64.35±13.74 and 64.39±13.55, the proportion of women in the improvement group and the remaining group are 50% and 41.6%. The rate of use of RAS system drugs and beta blockers improved by 96.4% and 89.3%, respectively, higher than the other group’s 86.1% and 74.5%, which is statistically significant. The rate of MRA, SGLT2-i in the improved group and the remaining group was 63.1%; 59.5% and 64.9%; 61.9%. The rate of using 2 drugs including RAS and beta blockers in the improvement group (85.7%) was statistically significantly higher than the other group (67.6%). The area under the ROC curve of admission EF, LVEDVi, LVESVi in predicting improvement was 0.687 (95% CI 0.640-0.730; p&lt; 0.001), respectively; 0.531(95% CI 0.462-0.599; p=0.378); 0.543 (95% CI 0.467-0.611; p=0.211). If only calculated on the total number of patients with EF ≤ 40%, the Kaplan Meier chart of CABG, heart valve surgery and percutaneous coronary intervention predicting improvement in heart failure after 3 months are all statistically significant. Conclusion: The rate of heart failure improved in the program was 17.2%. EF at admission, rate of use of RAS system drugs, beta blockers, rate of use of 2 RAS system drugs and beta blockers, percutaneous coronary intervention, CABG surgery or Heart valve surgery is significant in predicting improved heart failure in the heart failure program at Hanoi Heart Hospital.

Time-domain heart rate variability features for automatic congestive heart failure prediction.

Heart failure is a serious condition that often goes undiagnosed in primary care due to the lack of reliable diagnostic tools and the similarity of its symptoms with other diseases. Non-invasive monitoring of heart rate variability (HRV), which reflects the activity of the autonomic nervous system, could offer a novel and accurate way to detect and manage heart failure patients. This study aimed to assess the feasibility of using machine learning techniques on HRV data as a non-invasive biomarker to classify healthy adults and those with heart failure. We used digitized electrocardiogram recordings from 54 adults with normal sinus rhythm and 44 adults categorized into New York Heart Association classes 1, 2, and 3, suffering from congestive heart failure. All recordings were sourced from the PhysioNet database. Following data pre-processing, we performed time-domain HRV analysis on all individual recordings, including root mean square of the successive difference in adjacent RR interval (RRi) (RMSSD), the standard deviation of RRi (SDNN, the NN stands for natural or sinus intervals), the standard deviation of the successive differences between successive RRi (SDSD), the number or percentage of RRi longer than 50ms (NN50 and pNN50), and the average value of RRi [mean RR interval (mRRi)]. In our experimental classification performance evaluation, on the computed HRV parameters, we optimized hyperparameters and performed five-fold cross-validation using four machine learning classification algorithms: support vector machine, k-nearest neighbour (KNN), naïve Bayes, and decision tree (DT). We evaluated the prediction accuracy of these models using performance criteria, namely, precision, recall, specificity, F1 score, and overall accuracy. For added insight, we also presented receiver operating characteristic (ROC) plots and area under the ROC curve (AUC) values. The overall best performance accuracy of 77% was achieved when KNN and DT were trained on computed HRV parameters with a 5min time window. KNN obtained an AUC of 0.77, while DT attained 0.78. Additionally, in the classification of severe congestive heart failure, KNN and DT had the best accuracy of 91%, with KNN achieving an AUC of 0.88 and DT obtaining 0.92. The results show that HRV can accurately predict severe congestive heart failure. The findings of this study could inform the use of machine learning approaches on non-invasive HRV, to screen congestive heart failure individuals in primary care.

Heart failure early post-discharge appointment: a 1.5-year single-centre experience

Abstract Background According to Heart Failure (HF) guidelines, a follow-up visit should be conducted within 1 to 2 weeks after hospital discharge to monitor signs and symptoms of HF, optimize therapy, and evaluate treatment side effects. Retrospective studies have shown that this approach is associated with lower 30-day readmission rates. Purpose Our aim is to describe the role of early post-discharge appointment in the management of HF patients and to evaluate prognostic factors after HF hospitalization. Methods We conducted a single-centre prospective registry of consecutive patients evaluated in the early post-discharge appointment at our centre, from March 2021 to September 2022. HF symptoms, vital signs, blood test results, treatment decision, and 90-day HF events were recorded. Results Overall, 153 patients were included (mean age 65.7 ± 13.0 years, 63.4% male). The mean time from hospital discharge to post-discharge appointment was 13.4 ± 5.7 days. Left ventricle ejection fraction was reduced in 83.6% (n = 127) of patients. Guideline-directed medical treatment prescribed at discharge, as well as up-titration and withdrawal patterns at the post-discharge appointment, are presented in Table 1. At the post-discharge appointment, 34.3% of patients (n = 35) presented with drug adverse effects, most often including hyperkalemia (17.5%, n = 22), acute kidney injury (9.9%, n = 12), and hypotension (3.9%, n = 6). Of those evaluated at the post-discharge appointment, 11.2% (n = 17) were scheduled to another appointment one week later, for early re-evaluation, 90.1% (n = 137) were followed-up in the standard HF ambulatory program, and 2.6% (n = 4) were hospitalized. The serum creatinine (1.10 [0.87 – 1.36] mg/dL vs 1.40 [1.09 – 1.95] mg/dL, p&amp;lt;0.001), the serum C cystatin (1.50 [1.25 – 1.98] mg/dL vs 1.97 [1.54 – 2.46] mg/dL, p = 0.007) and the NT-proBNP levels (1859 [977 – 4877] mg/dL vs 5928 [2817 – 11957] mg/dL, p = 0.013), measured at the time of the post-discharge appointment, were found to be associated with HF events within 90 days (urgent HF visit or HF hospitalization). An NT-proBNP level above 2400 pg/mL adjusted to C cystatin was found to be a strong predictor of 90-day HF events (OR 9.855, 95% CI 2.657 – 36.550, p = 0.001). This model yielded a good prognostic performance (AUC 0.790, CI 95% 0.689-0.890, p&amp;lt;0.001). Conclusions Early evaluation of HF patients after hospital discharge allows for guideline-directed medical therapy up-titration and early detection of drug adverse effects. The NTproBNP level and kidney function, assessed early after discharge, have been found to be strong predictors of 90-day HF events, indicating which patients would benefit most from a stricter follow-up program. Table 1 – Guideline-directed medical therapy patterns of prescription both at hospital discharge and during the early post-discharge appointment. ACE, angiotensin converting enzyme; ARA, aldosterone receptor antagonist, MRA, mineralocorticoid receptor antagonist.

Impact of qualified nursing education on self-care and disease knowledge in heart failure patients

Abstract Purpose Guidelines on management of heart failure patients support intensive patient education on self-care. To evaluate the short and long-term impact of a structured education by a qualified heart failure nurse on patient´s self-care and disease knowledge. Methods 131 patients (66±12 years) hospitalized for heart failure participated in a structured one hour education program by a heart failure nurse. Patients completed a questionnaire consisting of 15 questions, nine of the European Heart Failure Self-Care Behaviour Scale (EHFScB-9) and additionally six questions on the patient´s disease knowledge 1 day before, 6 months and 12 months after the education course. Possible responses ranged from 1 (complete agreement) to 5 (complete disagreement). Clinical events during the 12 months follow-up period were determined. Factors predicting with potential impact on the teaching effect were evaluated. Seven patients refused further participation during follow-up, 13 patients were lost during follow-up, and one patient was excluded from the study due to progressive dementia. Results Nine patients died during the study and 33 patients had recurrent hospitalization for heart failure. EHFScB-9 scale improved from 24.0±7.2 at baseline to 17.0±7.4 (p&amp;lt;0.001) at 6 months, and 17.2±6.1 (p&amp;lt;0.001 vs. baseline) after 12 months. Concerning the disease knowledge score, it improved from 17.9±5.3 at baseline to 12.1±4.3 (p&amp;lt;0.05) at 6 months follow-up, and to 12.0±5.5 (p&amp;lt;0.05) at 12 months after education. Scores to individual questions prior to education ranged from 1.2±0.8 on adherence to the medication protocol to 2.7±1.4 on everyday weighting habits. Greatest improvement after education were obtained on reaction to weight gains (-1.9±1.3), daily weight control (-1.6±1.4) and knowledge on the reason of patient’s heart failure (-1.6±1.2). The NYHA-classification improved from 2.8±0.8 before teaching to 2.2±0.7 (p&amp;lt;0.001) at 12-months follow-up. No predictor of an insufficient teaching effect could be defined. Patients with a clinical event (death, recurrent hospitalization) had a combined EHFScB-9 and disease knowledge score of 32.6±8.1vs. 28.9±9.9 in those patients without a clinical event. Patients with more than one hospitalization due to acute decompensated heart failure during the follow-up period express insignificant improvement of the combined EHFScB-9 and disease knowledge score immediately after the education session. Conclusions A qualified nurse education program improves self-care behaviour and patient´s disease knowledge with a persisting effect at 6 and 12 months follow-up. There are no patient characteristics which preclude the implementation of an educational session.

Abstract 13644: Management Patterns in Patients With Heart Failure: Insights From iCaReMe Global Registry

Introduction: Heart failure (HF) is an increasing major case of morbidity and mortality, including in low and middle income countries (LMIC) due to the rising incidence of HTN, T2D and CKD. Little information is available on the management of HF in LMIC. iCaReMe is a unique ongoing registry collecting data from contemporary routine clinical practice in patients with HF, T2D, HTN and/or CKD. Aims: Describe clinical characteristics, comorbidities and management of HF patients based on data from iCaReMe Registry. Methods: iCaReMe Global Registry (NCT03549754) is a multinational, prospective, observational study to assess the management and quality of care in patients with HF, T2D, HTN and/or CKD. We present baseline descriptive analysis of the HF cohort enrolled from February 2018 to December 2022. Results: A total of 3069 adults (mean age±SD 58.7±12.6 years, 59.2% males, 40.3% obese) with HF from 21 countries were evaluated in this initial report. Of the 2307 (75.2%) patients with available LVEF data; 63.4% had HFrEF, 14.3% HFmrEF, and 22.3% HFpEF. The median (IQR) LVEF was 36(30-47) % and 83% had NYHA class II-IV symptoms. Overall, 27.1% of patients reported history of hospitalization for HF. The comorbidities were common including T2D (60.4%), HTN (57.1%), CAD (45.4%), dyslipidemia (36.0%), and CKD (30.5%). In patients with available data, the mean UACR was 282.5 mg/g [reported in 666 (21.7%) patients] and mean eGFR was 70.3 ml/min/1.73m 2 [reported in 2325 (75.8%) patients]. The medications included ACEi or ARB in 66.6%, ARNI in 15.9%, b-blockers in 65%, MRA in 38.7%, and SGLT2i in 40.3%. Conclusions: iCaReMe Registry provides a unique perspective on the characteristics and management of patients with HF in low and middle income countries and demonstrates substantial burden of multimorbidity. The data highlight gaps between guidelines and routine care and the need to identify and address barriers to the implementation of optimal management and evidence-based therapies.

Non-invasive and contemporaneous cardiac imaging in heart failure

This article reviews the current non-invasive cardiac imaging modalities used in the diagnosis and management of heart failure patients. Heart failure is a complex syndrome secondary to functional and structural changes of the heart, with a wide range of possible causes for its onset. Different imaging investigations can inform diagnosis and guide care plans, so nurses across clinical practice will benefit from having knowledge on when these modalities are used. Echocardiography remains the most common investigation due to its low cost and reproducible nature when compared with other methods. It allows quantification of left ventricular function, which is an important prognostic marker in heart failure. Through cardiac magnetic resonance imaging, identification of potential reversible causes is possible, and further identification of underlying causes, when other modalities fail to do so. Finally, computed tomography coronary angiography is the currently recommended test in all patients presenting with typical or atypical anginal symptoms, diagnostically comparable to invasive coronary angiography.

The role of laboratory medicine in a value-based healthcare system: the example of heart failure patient management in the Italian context.

As of today, healthcare systems worldwide face severe challenges that undermine their sustainability. The value-based healthcare (VBHC) approach has been proposed as a strategic and methodological framework to ensure the delivery of the best patient outcomes with economic efficiency. Through the illustrative example of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) for heart failure (HF) patient management in the context of the Italian National Healthcare system, this article explores the role that in vitro diagnostics (IVDs) can play in enabling value-based care models. 14 healthcare professionals representing the relevant professional figures involved in HF patient management met to revise the current HF patient journey and design a new care pathway that, leveraging on BNP/NT-proBNP, reflects the VBHC principles. The literature recognizes the dosage of BNP/NT-proBNP as the gold stan-dard for diagnosing HF. However, as of today, these IVDs are not employed at their full potential regarding HF patient management. A new patient journey is proposed so that patients are diagnosed early and properly monitored in the aftermath of hospitalization, improving outcomes at contained costs. As testified by the example of HF patient management in Italy, laboratory medicine can represent a lever for adopting value-based care models. Still, large-scale adoption of VBHC will call for structural reforms that revise how healthcare delivery is organized, measured, and reimbursed.